Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - CRISPR Therapeutics AG | d382380dex312.htm |
| EX-31.1 - EX-31.1 - CRISPR Therapeutics AG | d382380dex311.htm |
| 10-Q - FORM 10-Q - CRISPR Therapeutics AG | d382380d10q.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of CRISPR Therapeutics AG (the “Company”) for the period ended March 31, 2017 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), the undersigned officers of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his or her knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report. |
| /s/ Rodger Novak |
| Rodger Novak Chief Executive Officer (Principal Executive Officer) |
| May 11, 2017 |
| /s/ Samarth Kulkarni |
| Samarth Kulkarni President and Chief Business Officer (Principal Financial Officer) |
| May 11, 2017 |